… This study included 25 patients with stage IIIb or IV non-squamous cell, non-small cell lung
… to upfront TKI treatment (gefitinib 250 mg/d or erlotinib150 mg/d) were treated with multi-…

… Forty-two patients with lung adenocarcinoma were reviewed in the present study. All … All
patients in the present study were affected by rash of some grade while receiving erlotinib. The …

… study, the primary objective was to determine the pooled overall treatment effect on OS of
firstline therapy with gefitinib … this meta-analysis of gefitinib and erlotinib as most of the included …

… No study has compared these two generations of EGFR-TKIs … retrospective study to assess
the efficacy of gefitinib/erlotinib … between the gefitinib/erlotinib and afatinib treatment groups, …

… Gefitinib and erlotinib have been widely used to treat advanced NSCLC during the past
decade. By analyzing 40 high quality studies, we compared the antitumor effectiveness and …

… Erlotinib has an established role in the treatment of advanced, … Erlotinib and gefitinib are
reversible tyrosine kinase … In the Phase I study of erlotinib in combination with carboplatin and …

… This study aims to compare the effectiveness of first line TKIs; gefitinib, erlotinib, and
afatinib in the treatment of advanced stage NSCLC patients with EGFR mutation positive in the …

… discretion in this study, the TKI treatment chosen for patients with brain metastasis may
have been affected by physician awareness of previous studies favoring erlotinib or afatinib in …

… of the present study suggested that shikonin could promote erlotinib/gefitinib-induced apoptosis
… The dose of erlotinib/gefitinib selected in the present study was not expected to exhibit …

… of this study were to compare the efficacy among three first-generation EGFR-TKIs as adjuvant
treatment … Finally, treatment selection bias was inevitable in this study; however, since all …